Knowledge Center

The Strategic Marketplace Initiative (SMI) is a consortium of healthcare supply chain executives united to re-engineer and advance the future of the healthcare supply chain. SMI has provided AHRMM with free supply chain industry resources. To access the resources, visit www.smisupplychain.com or click on the topic below. You will be prompted to register with SMI in order to access the free tools.

Recent Guidance on Meaningful Use of EHRs Makes Compliance More Difficult.

  View a copy of the survey report (PDF)  

AHRMM's Cost, Quality, and Outcomes (CQO) Movement will provide training and education to help supply chain professionals make the correlation between cost, quality, and outcomes.

Review Supply Chain Analyst job description and tasks.

In the fall of 2014, the University of Houston conducted a national study on hospital supply chain. With the support and participation from the AHRMM community, the University of Houston collected data from 266 hospitals and at least 60 percent of the respondents have an official designation of supply chain director or higher. Thank you to those who participated in the study. Your contribution is invaluable in helping academic institutions, AHRMM, and collaborating organizations better understand supply chain perspectives and best practices.  

An announcement of the Final Rule issued by the IRS.

The Medical Device Excise Tax, a component of the Affordable Care Act, is approaching implementation at the beginning of 2013. The tax is intended to provide an estimated $20 billion in tax revenues to help pay for the expansion of health coverage to 32 million uninsured Americans. Healthcare supply chain leaders have until May 7, 2012, to comment on the way in which the Internal Revenue Service (IRS) intends to implement this new tax.

Supply chain must play an integral role in the care delivery process through cross-departmental partnerships that support evidence-based value analysis. Michael Louviere, System VP of Supply Chain at OHS shares his insights on what he calls a 'new adventureattempting to support best practices by collecting clinical evidence and synthesizing it to ensure that clinical practice is based on integrating individual clinical expertise with the best available relevant external clinical evidence from systematic research.

November is Critical Infrastructure Security and Resilience Month.

How-to guide to managing IV disruptions. Download Tool

The medical device excise tax is a feature of the Affordable Care Act. It is important to be knowledgeable about the tax and its effects.

Senior Contract Specialist job description.

The Food and Drug Administration (FDA) UDI system is being phased in over several years. The first sunrise date (certain Class III devices) occurred 09/24/14. Recognizing UDI implementation will take time, healthcare supply chain and risk management professionals should be aware of already-implemented changes in the FDA’s adverse event reporting methodology. One of the changes required immediately is the use of the UDI in adverse event reporting.

How to write a constructive, information-rich comment that clearly communicates and supports its claims to have an impact on regulatory decision making.

The FDA UDI ruling has finally arrived - the proposed rule has published. Please see the FDA website (www.fda.gov/udi) for a link to the proposed regulation. Highlights include a 120 day comment period to begin shortly, 6 months later a final ruling that will begin with Class III devices within 2 years, possibly sooner. Below is the FDA press release:

On November 21, 2013, AHRMM submitted electronically

The final regulations that provide guidance on the excise tax imposed on the sale of certain medical devices, enacted by the Health Care and Education Reconciliation Act of 2010 in conjunction with the Patient Protection and Affordable Care Act.

An overview of Fiscal Year (FY) 2015 Hospital Value-Based Purchasing (VBP) Program.

AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA).